A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors

NCT02799095 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

243

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: ALKS 4230
DRUG: ALKS 4230 + pembrolizumab

Sponsor

Mural Oncology, Inc